| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $559.5M | -7.4% |
| Cost of Revenue | $340.2M | -2.4% |
| Gross Profit | $219.3M | -14.1% |
| R&D Expense | $12.4M | -18.4% |
| SG&A Expense | $95.0M | -16.3% |
| Operating Income | -$97.7M | -3219.5% |
| Pre-tax Income | -$119.3M | -231.8% |
| Income Tax | -$4.1M | -111.7% |
| Net Income | -$115.2M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $19.6M | +31.0% |
| Accounts Receivable | $82.1M | -3.8% |
| Inventory | $98.8M | -8.0% |
| Current Assets | $214.8M | -11.6% |
| Total Assets | $676.0M | -18.6% |
| Current Liabilities | $80.1M | -34.5% |
| Long-term Debt | $403.3M | -0.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $20.5M | -14.1% |
| Capital Expenditures | $6.9M | -42.2% |
| Investing Cash Flow | -$7.3M | +40.5% |
| Financing Cash Flow | -$8.5M | +67.8% |
| Free Cash Flow | $13.6M | +14.2% |
| -238.7% |
| EPS (Basic) | -$0.87 | -222.2% |
| EPS (Diluted) | -$0.87 | -222.2% |
| Total Liabilities |
| $505.1M |
| -8.9% |
| Stockholders' Equity | $170.8M | -38.2% |